Actively Recruiting

Phase 2
Age: 12Years - 35Years
All Genders
NCT06111586

FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)

Led by Sanofi · Updated on 2026-04-08

192

Participants Needed

80

Research Sites

359 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening period: at least 3 weeks and up to 5 weeks Double-blind treatment period (104 weeks): * Main treatment period: 52 weeks * Blinded extension: 52 weeks Optional Open Label Extension: 104 weeks Safety follow-up: up to 26 weeks The treatment duration will be up to 104 weeks, the total study duration will be up to 135 weeks.

CONDITIONS

Official Title

FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)

Who Can Participate

Age: 12Years - 35Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants diagnosed with Type 1 Diabetes according to American Diabetes Association criteria
  • Started insulin treatment no more than 90 days before screening
  • Currently receiving insulin therapy via multiple daily injections or continuous infusion
  • Positive for at least one Type 1 Diabetes autoantibody (GAD-65, IA-2, ZnT8, or Insulin)
  • Random C-peptide level at screening of 0.2 nmol/L or higher
  • Up to date with local vaccination schedule; vaccinations must be completed at least 28 days prior for non-live vaccines and 3 months prior for live vaccines
  • Use of contraception consistent with local regulations for men and women participating in clinical studies
Not Eligible

You will not qualify if you...

  • Serious infections requiring hospitalization or intravenous antibiotics within 30 days before screening
  • History of invasive opportunistic infections regardless of resolution
  • Evidence of active or latent tuberculosis
  • Clinically significant unstable or severe medical conditions that could affect safety
  • History of low antibody levels (hypogammaglobulinemia)
  • Severe allergies or hypersensitivity to humanized monoclonal antibodies
  • Other autoimmune diseases requiring biologic or systemic corticosteroid treatment
  • History or risk of blood clots, heart attack, stroke, or related disorders
  • Diabetes types other than autoimmune Type 1 Diabetes
  • Cancer treated or untreated within the past 5 years
  • Use of systemic corticosteroids longer than 7 days within 1 month prior to screening
  • Use of biologic treatments within 3 months or five half-lives prior to randomization
  • Receipt of live vaccines within 3 months prior to randomization
  • Receipt of non-live vaccines within 28 days prior to randomization
  • Use of medications incompatible with the investigational drug
  • Immunosuppressive therapy within 12 weeks prior to randomization
  • Previous treatment with immunomodulatory drugs like Thymoglobulin or teplizumab
  • Use of diabetes drugs other than insulin within 2 weeks prior to screening
  • Abnormal laboratory tests at screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 80 locations

1

University of California San Francisco - Mission Bay- Site Number : 8400012

San Francisco, California, United States, 94158

Actively Recruiting

2

University of Colorado - Anschutz Medical Campus- Site Number : 8400003

Aurora, Colorado, United States, 80045

Actively Recruiting

3

University of Florida College of Medicine- Site Number : 8400010

Gainesville, Florida, United States, 32610

Actively Recruiting

4

University of Miami Hospital- Site Number : 8400013

Miami, Florida, United States, 33136

Actively Recruiting

5

AdventHealth Orlando- Site Number : 8400002

Orlando, Florida, United States, 32803

Actively Recruiting

6

Rocky Mountain Diabetes and Osteoporosis Center- Site Number : 8400009

Idaho Falls, Idaho, United States, 83404

Actively Recruiting

7

NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400007

Skokie, Illinois, United States, 60077

Actively Recruiting

8

Joslin Diabetes Center - Boston- Site Number : 8400015

Boston, Massachusetts, United States, 02215

Actively Recruiting

9

University at Buffalo - Downtown Campus- Site Number : 8400004

Buffalo, New York, United States, 14203

Actively Recruiting

10

University of North Carolina at Chapel Hill- Site Number : 8400001

Chapel Hill, North Carolina, United States, 27514

Actively Recruiting

11

Cincinnati Children's Hospital Medical Center- Site Number : 8400019

Cincinnati, Ohio, United States, 45229

Actively Recruiting

12

The Children's Hospital of Philadelphia Site Number : 8400005

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

13

University of Texas - Southwestern Medical Center- Site Number : 8400011

Dallas, Texas, United States, 75390

Actively Recruiting

14

Benaroya Research Institute at Virginia Mason- Site Number : 8400016

Seattle, Washington, United States, 98101

Actively Recruiting

15

Investigational Site Number : 0400002

Graz, Austria, 8036

Actively Recruiting

16

Investigational Site Number : 0400004

Linz, Austria, 4020

Actively Recruiting

17

Investigational Site Number : 0400001

Vienna, Austria, 1090

Actively Recruiting

18

Investigational Site Number : 0560002

Brussels, Belgium, 1090

Actively Recruiting

19

Investigational Site Number : 0560001

Leuven, Belgium, 3000

Actively Recruiting

20

Investigational Site Number : 1240001

Vancouver, British Columbia, Canada, V5Y 3W2

Actively Recruiting

21

Investigational Site Number : 1240007

London, Ontario, Canada, N6A 5W9

Actively Recruiting

22

Investigational Site Number : 1240005

Montreal, Quebec, Canada, H3T 1C5

Actively Recruiting

23

Investigational Site Number : 1240004

Montreal, Quebec, Canada, H4A 3J1

Actively Recruiting

24

Investigational Site Number : 1240003

Montreal, Quebec, Canada, H4A 3T2

Actively Recruiting

25

Investigational Site Number : 2030003

Ostrava, Czechia, 708 52

Actively Recruiting

26

Investigational Site Number : 2030002

Prague, Czechia, 100 34

Actively Recruiting

27

Investigational Site Number : 2030001

Prague, Czechia, 150 06

Actively Recruiting

28

Investigational Site Number : 2080005

Herlev, Denmark, 2730

Actively Recruiting

29

Investigational Site Number : 2460001

Helsinki, Finland, 00290

Actively Recruiting

30

Investigational Site Number : 2460004

Oulu, Finland, 90220

Actively Recruiting

31

Investigational Site Number : 2460003

Tampere, Finland, 33520

Actively Recruiting

32

Investigational Site Number : 2460002

Turku, Finland, 20521

Actively Recruiting

33

Investigational Site Number : 2500004

Corbeil-Essonnes, France, 91106

Actively Recruiting

34

Investigational Site Number : 2500005

Mont-de-Marsan, France, 40024

Actively Recruiting

35

Investigational Site Number : 2500006

Paris, France, 75679

Actively Recruiting

36

Investigational Site Number : 2500007

Pontoise, France, 95300

Actively Recruiting

37

Investigational Site Number : 2500003

Saint-Herblain, France, 44800

Actively Recruiting

38

Investigational Site Number : 2760003

Dresden, Germany, 01307

Actively Recruiting

39

Investigational Site Number : 2760001

Hanover, Germany, 30173

Actively Recruiting

40

Investigational Site Number : 2760002

Oldenburg in Holstein, Germany, 23758

Actively Recruiting

41

Investigational Site Number : 2760004

Ulm, Germany, 89081

Actively Recruiting

42

Investigational Site Number : 3480001

Balatonfüred, Hungary, 8230

Actively Recruiting

43

Investigational Site Number : 3480004

Budapest, Hungary, 1089

Actively Recruiting

44

Investigational Site Number : 3480002

Nyíregyháza, Hungary, 4400

Actively Recruiting

45

Investigational Site Number : 3480003

Nyíregyháza, Hungary, 4400

Actively Recruiting

46

Investigational Site Number : 3480006

Székesfehérvár, Hungary, 8000

Actively Recruiting

47

AOU delle Marche - Ospedale G. Salesi-Site Number : 3800008

Torette, Ancona, Italy, 60020

Actively Recruiting

48

Azienda Ospedaliera Universitaria Meyer IRCCS-Site Number : 3800003

Florence, Firenze, Italy, 50139

Active, Not Recruiting

49

IRCCS Ospedale San Raffaele-Site Number : 3800006

Milan, Milano, Italy, 20132

Actively Recruiting

50

Azienda Ospedaliera Universitaria 'Federico II'-Site Number : 3800009

Naples, Napoli, Italy, 80131

Active, Not Recruiting

51

Ospedale Pediatrico Bambin Gesu IRCCS-Site Number : 3800007

Rome, Roma, Italy, 00165

Active, Not Recruiting

52

Azienda Ospedaliero-Universitaria Maggiore Della Carità-Site Number : 3800001

Novara, Italy, 28100

Actively Recruiting

53

Azienda Socio Sanitaria Territoriale Dei Sette Laghi - Ospedale Filippo del Ponte-Site Number : 3800002

Varese, Italy, 21100

Completed

54

Azienda Ospedaliera Universitaria Integrata Verona - Centro regionale di Diabetologia Pediatrica-Site Number : 3800004

Verona, Italy, 37126

Actively Recruiting

55

Investigational Site Number : 6160005

Lodz, Lódzkie, Poland, 92-213

Actively Recruiting

56

Investigational Site Number : 6160006

Warsaw, Masovian Voivodeship, Poland, 02-097

Actively Recruiting

57

Investigational Site Number : 6160004

Warsaw, Masovian Voivodeship, Poland, 02-117

Actively Recruiting

58

Investigational Site Number : 6160001

Warsaw, Masovian Voivodeship, Poland, 02-507

Actively Recruiting

59

Investigational Site Number : 6160007

Warsaw, Masovian Voivodeship, Poland, 04-746

Actively Recruiting

60

Investigational Site Number : 6160008

Bialystok, Podlaskie Voivodeship, Poland, 15-274

Actively Recruiting

61

Investigational Site Number : 6160002

Katowice, Silesian Voivodeship, Poland, 40-752

Actively Recruiting

62

Investigational Site Number : 6160009

Szczecin, West Pomeranian Voivodeship, Poland, 71-252

Actively Recruiting

63

Investigational Site Number : 7050001

Ljubljana, Slovenia, 1000

Actively Recruiting

64

Investigational Site Number : 7240001

Barcelona, Barcelona [Barcelona], Spain, 08035

Actively Recruiting

65

Investigational Site Number : 7240002

Esplugues de Llobregat, Barcelona [Barcelona], Spain, 08950

Actively Recruiting

66

Investigational Site Number : 7240005

Oviedo, Principality of Asturias, Spain, 33011

Actively Recruiting

67

Investigational Site Number : 7240003

Seville, Sevilla, Spain, 41009

Actively Recruiting

68

Investigational Site Number : 7240004

Málaga, Spain, 29010

Actively Recruiting

69

Investigational Site Number : 7240006

Valencia, Spain, 46010

Actively Recruiting

70

Investigational Site Number : 7240007

Vitoria-Gasteiz, Álava, Spain, 01009

Actively Recruiting

71

Investigational Site Number : 7520002

Solna, Sweden, 171 64

Actively Recruiting

72

Investigational Site Number : 7520001

Stockholm, Sweden, 113 65

Actively Recruiting

73

Investigational Site Number : 7520003

Stockholm, Sweden, 118 83

Actively Recruiting

74

Investigational Site Number : 8260001

Cambridge, Cambridgeshire, United Kingdom, CB2 2QQ

Active, Not Recruiting

75

Investigational Site Number : 8260009

Dundee, Dundee City, United Kingdom, DD1 9SY

Actively Recruiting

76

Investigational Site Number : 8260003

Birmingham, England, United Kingdom, B15 2TH

Actively Recruiting

77

Investigational Site Number : 8260007

Birmingham, England, United Kingdom, B4 6NH

Active, Not Recruiting

78

Investigational Site Number : 8260010

Glasgow, Glasgow City, United Kingdom, G51 4TF

Active, Not Recruiting

79

Investigational Site Number : 8260004

Leicester, Leicestershire, United Kingdom, LE5 4PW

Actively Recruiting

80

Investigational Site Number : 8260006

Harrow, London, City of, United Kingdom, HA1 3UJ

Active, Not Recruiting

Loading map...

Research Team

T

Trial Transparency email recommended (Toll free number for US & Canada)

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here